NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Shattuck Labs, Inc. STTK
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.0M
▼ 82.5% vs FY2024
EPS · FY25
$-0.70
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-60.3%
Net margin · FY25
-4880.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.0M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 4881 cents on every revenue dollar this year.
Per share
USD -0.70
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-60.3%
Return on equity, FY2025
ROE
Operating margin-5150.8%
Net margin-4880.9%
Return on assets-53.6%
Each USD of equity lost 60 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−36.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+15.3%
−36.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+51.5%
Change, 10 years—
The share count grew 52% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 91.0M
total assets, end of FY2025
Total assetsUSD 91.0M
EquityUSD 82.4M
CashUSD 54.2M
Current ratio11.70×
Equity funds 91% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.70
−1.49
−2.05
−2.41
−1.07
−2.36
−3.17
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−60.3
−67.2
−54.4
−45.5
−15.5
−26.6
·
Shares out B
0.06
0.05
0.05
0.04
0.04
0.04
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed